Health Services Stocks On The Rise With Help From 5 Stocks

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Two out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 40 points (0.3%) at 15,878 as of Tuesday, Jan. 28, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,973 issues advancing vs. 972 declining with 141 unchanged.

The Health Services industry currently sits up 0.6% versus the S&P 500, which is up 0.3%. Top gainers within the industry include Waters Corporation ( WAT), up 7.0%, PerkinElmer ( PKI), up 3.1%, Align Technology ( ALGN), up 2.7%, Grifols ( GRFS), up 2.1% and Mettler-Toledo International ( MTD), up 1.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Stryker Corporation ( SYK) is one of the companies pushing the Health Services industry higher today. As of noon trading, Stryker Corporation is up $0.41 (0.5%) to $76.73 on light volume. Thus far, 246,161 shares of Stryker Corporation exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $76.53-$77.07 after having opened the day at $76.75 as compared to the previous trading day's close of $76.32.

Stryker Corporation, a medical technology company, provides reconstructive, medical and surgical, and neurotechnology and spine products for doctors, hospitals, and other healthcare facilities. Stryker Corporation has a market cap of $28.8 billion and is part of the health care sector. The company has a P/E ratio of 18.0, above the S&P 500 P/E ratio of 17.7. Shares are up 1.6% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Stryker Corporation a buy, 1 analyst rates it a sell, and 10 rate it a hold.

TheStreet Ratings rates Stryker Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Stryker Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Covidien ( COV) is up $1.29 (1.9%) to $69.00 on average volume. Thus far, 1.0 million shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $67.74-$69.35 after having opened the day at $67.83 as compared to the previous trading day's close of $67.71.

Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $30.8 billion and is part of the health care sector. The company has a P/E ratio of 19.8, above the S&P 500 P/E ratio of 17.7. Shares are down 0.6% year-to-date as of the close of trading on Monday. Currently there are 14 analysts who rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, HCA Holdings ( HCA) is up $0.50 (1.0%) to $49.60 on light volume. Thus far, 612,593 shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.1 million shares. The stock has ranged in price between $48.99-$50.04 after having opened the day at $49.05 as compared to the previous trading day's close of $49.10.

HCA Holdings, Inc., through its subsidiaries, provides health care services. HCA Holdings has a market cap of $21.7 billion and is part of the health care sector. The company has a P/E ratio of 15.5, below the S&P 500 P/E ratio of 17.7. Shares are up 2.9% year-to-date as of the close of trading on Monday. Currently there are 15 analysts who rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share and poor profit margins. Get the full HCA Holdings Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Thermo Fisher Scientific ( TMO) is up $1.64 (1.5%) to $111.51 on average volume. Thus far, 917,456 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $110.59-$112.04 after having opened the day at $110.59 as compared to the previous trading day's close of $109.87.

Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $39.7 billion and is part of the health care sector. The company has a P/E ratio of 30.3, above the S&P 500 P/E ratio of 17.7. Shares are down 1.3% year-to-date as of the close of trading on Monday. Currently there are 12 analysts who rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, reasonable valuation levels, growth in earnings per share and expanding profit margins. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Thermo Fisher Scientific Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Express Scripts ( ESRX) is up $1.12 (1.5%) to $74.47 on light volume. Thus far, 1.5 million shares of Express Scripts exchanged hands as compared to its average daily volume of 4.5 million shares. The stock has ranged in price between $73.62-$74.84 after having opened the day at $73.84 as compared to the previous trading day's close of $73.35.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services primarily in the United States and Canada. It offers healthcare management and administration services on behalf of its clients. Express Scripts has a market cap of $59.1 billion and is part of the health care sector. The company has a P/E ratio of 31.7, above the S&P 500 P/E ratio of 17.7. Shares are up 4.4% year-to-date as of the close of trading on Monday. Currently there are 13 analysts who rate Express Scripts a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, good cash flow from operations, solid stock price performance, growth in earnings per share and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Express Scripts Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Apple Suppliers Slide After European, Asian Chipmakers Echo Smartphone Concerns

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

Global Stocks Edge Higher, But Bond Yields, Oil Prices May Test Market Strength

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

SAP Shares Leap After Cloud Business Prompts Full-Year Guidance Upgrade

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%